Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer

Sponsor
The First Affiliated Hospital of Xiamen University
Study ID
NCT04572542
Phase
PHASE1/PHASE2
Status
Unknown

Conditions

  • Locally Advanced or Metastatic Gastric Adenocarcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab — DRUG
    Camrelizumab One course will last 21 days.Given once every 3 weeks at a dose of 200 mg
  • Apatinib Mesylate — DRUG
    Apatinib One course will last 21 days.Oral administration at a dose of 250 mg everyday
  • nab-paclitaxel — DRUG
    nab-paclitaxel One course will last 21 days。Given twice every 3 weeks at a dose of 125 mg/m2

Study Details

To evaluate the clinical efficacy and safety of camrelizumab combined with apatinib mesylate and nab-paclitaxel .

Key Dates

Start date
Jan 1, 2020
Status verified
Sep 2020
Primary completion
Jun 1, 2021
Completion
Jun 1, 2022

Study Design

Enrollment
46 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Camrelizumab + Apatinib + nab-paclitaxel
    Camrelizumab combined with Apatinib mesylate tablets and nab-paclitaxel in the second-line treatment of advanced gastric cancer

Primary Outcome Measure

Objective response rate [ Time Frame: one year ]

Central Contacts